Molecular Biomarkers Predicting Efficacy Of Introgen Therapeutics, Inc.'s ADVEXIN Cancer Therapy Are Highlighted At Major Cancer Conference

CHICAGO, Sept. 15 /PRNewswire-FirstCall/ -- News of Introgen Therapeutics, Inc.'s (Nasdaq: INGN - News) use of a molecular biomarker to predict the efficacy of its ADVEXIN cancer therapy was released yesterday by the American Association for Cancer Research (AACR). Introgen has reached agreement with the U.S. Food and Drug Administration (FDA) to incorporate the use of Introgen's p53 molecular biomarkers in the analysis of ADVEXIN clinical data used in support of FDA submissions for approval. Data were presented at the AACR International Conference on Molecular Diagnostics in Cancer Therapeutic Development in Chicago. The AACR news release is entitled, "Abnormal Overexpression of p53 is a Predictive Molecular Biomarker of Advexin Efficacy in Recurrent Squamous Cell Carcinoma of the Head and Neck" and can be found at: http://www.aacr.org/Default.aspx?p=1275&d=652 .